FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
What happened
FDA reviewed the website joinweightcare.com in December 2025 and found it offering compounded semaglutide and tirzepatide drug products. The product labels pictured on the site show the name "WeightCare," which suggests WeightCare made the drugs when it did not. FDA says that makes the products misbranded (misbranded means the labeling is false or misleading).
What FDA found
The website labeling is false or misleading because it presents WeightCare as the maker of the drugs.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising or promotion of a compounded drug is false or misleading when it misstates who compounds it.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Putting a company's name on a drug label without qualification says that company is the only manufacturer, which is false here.
21 CFR § 201.1(h)(2)Shipping misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving or delivering misbranded drugs is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]Compounded drugs must meet the conditions of sections 503A or 503B to be exempt from the new drug approval requirements.
FDCA sections 503A and 503B [21 U.S.C. §§ 353a, 353b]
What FDA wants
Within 15 working days, send the Office of Compounding Quality and Compliance a written response describing the steps taken to fix the violations and prevent them from recurring. Include who actually compounds the products, sample labeling, and the basis for other website claims or evidence that they were changed or removed.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies whose products are resold under another brand
- marketing and compliance teams that write product pages and labels for online pharmacies
This is a summary. Read the original letter on fda.gov.